Thomas Dayspring challenges the notion of "good" and "bad" cholesterol, arguing that it's the actions of lipoproteins that determine their impact, not the cholesterol molecule itself. He explains how HDL and LDL particles interact and emphasizes the importance of understanding cholesterol pathways. Peter Attia adds insights on the Framingham study and the misconceptions surrounding it.
